Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director | May 26, 2021 | May 28, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date May 26, 2021 · Filed May 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,800 |
Reported balance
After 2021-05-26 transaction · row 1
1 source rowRow 1 · 2021-05-26 · Grant · Acquired 4,700 · Balance 37,800 F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.86 · Expires 2031-05-25 | Direct | 7,800 |
Reported balance
After 2021-05-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-26 · Grant · Acquired 7,800 · Balance 7,800 F2: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
F2: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2021 Filed May 28, 2021 23:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $20.86 | $0.00 |
DisclosureSEC source: 0001209191-21-036681 · doc4.xml · derivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-05-25 F2 · derivative.exercise_date: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 23:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036681 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,800 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 00:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001209191-21-012546 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 00:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 844 | $52.93 | $44,672.92 |
DisclosureSEC source: 0001209191-21-012546 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,100 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $52.76 to $53.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 00:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,156 | $52.31 | $269,710.36 |
DisclosureSEC source: 0001209191-21-012546 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,944 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $51.76 to $52.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 00:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $28.65 | $171,900.00 |
DisclosureSEC source: 0001209191-21-012546 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $19.05 | $0.00 |
DisclosureSEC source: 0001209191-21-004751 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2026-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $43.38 | $260,280.00 |
DisclosureSEC source: 0001209191-21-004751 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,100 F1 · kind: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $19.05 | $114,300.00 |
DisclosureSEC source: 0001209191-21-004751 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2021 Filed Jan 16, 2021 01:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,999 | $0.00 Strike: $19.05 | $0.00 |
DisclosureSEC source: 0001209191-21-003917 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 5,999 shares Expires 2026-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| January 14, 2021 Filed Jan 16, 2021 01:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,999 | $40.04 | $240,199.96 |
DisclosureSEC source: 0001209191-21-003917 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,100 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $40.00 to $40.07. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 14, 2021 Filed Jan 16, 2021 01:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 5,999 | $19.05 | $114,280.95 |
DisclosureSEC source: 0001209191-21-003917 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 23:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1 | $0.00 Strike: $19.05 | $0.00 |
DisclosureSEC source: 0001209191-20-065571 · doc4.xml · derivative · entry 6 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,999 Underlying: Common Stock · 1 shares Expires 2026-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 23:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $18.34 | $0.00 |
DisclosureSEC source: 0001209191-20-065571 · doc4.xml · derivative · entry 5 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2025-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 23:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 100 | $41.14 | $4,114.00 |
DisclosureSEC source: 0001209191-20-065571 · doc4.xml · nonDerivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,100 F1 · kind: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 23:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,901 | $40.39 | $238,341.39 |
DisclosureSEC source: 0001209191-20-065571 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,200 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $40.00 to $40.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 23:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 1 | $19.05 | $19.05 |
DisclosureSEC source: 0001209191-20-065571 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 23:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $18.34 | $110,040.00 |
DisclosureSEC source: 0001209191-20-065571 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 00:30 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $32.69 | $0.00 |
DisclosureSEC source: 0001209191-20-035153 · doc4.xml · derivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2030-06-03 F2 · derivative.exercise_date: Options vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 00:30 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035153 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,100 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 02:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $18.34 | $0.00 |
DisclosureSEC source: 0001209191-20-009045 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 02:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $42.69 | $256,140.00 |
DisclosureSEC source: 0001209191-20-009045 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $42.41 to $43.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 02:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $18.34 | $110,040.00 |
DisclosureSEC source: 0001209191-20-009045 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2020 Filed Jan 9, 2020 02:14 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002652 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2024-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| January 06, 2020 Filed Jan 9, 2020 02:14 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $42.66 | $255,960.00 |
DisclosureSEC source: 0001209191-20-002652 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $42.23 to $43.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 06, 2020 Filed Jan 9, 2020 02:14 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $18.00 | $108,000.00 |
DisclosureSEC source: 0001209191-20-002652 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 23:08 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-19-060273 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2024-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 23:08 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $47.50 | $285,000.00 |
DisclosureSEC source: 0001209191-19-060273 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $47.10 to $47.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 23:08 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $18.00 | $108,000.00 |
DisclosureSEC source: 0001209191-19-060273 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 23:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001209191-19-055866 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2023-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 23:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,486 | $38.85 | $57,731.10 |
DisclosureSEC source: 0001209191-19-055866 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $38.65 to $39.095. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 23:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,514 | $38.08 | $171,893.12 |
DisclosureSEC source: 0001209191-19-055866 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,886 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $37.655 to $38.63. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 23:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $9.78 | $58,650.00 |
DisclosureSEC source: 0001209191-19-055866 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2019 Filed Oct 10, 2019 00:26 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001209191-19-052867 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2023-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| October 07, 2019 Filed Oct 10, 2019 00:26 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $36.73 | $220,380.00 |
DisclosureSEC source: 0001209191-19-052867 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $36.33 to $37.24. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2019 Filed Oct 10, 2019 00:26 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $9.78 | $58,650.00 |
DisclosureSEC source: 0001209191-19-052867 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 00:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-19-049099 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2022-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 00:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 420 | $41.67 | $17,501.40 |
DisclosureSEC source: 0001209191-19-049099 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $41.64 to $41.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 00:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,580 | $40.90 | $228,222.00 |
DisclosureSEC source: 0001209191-19-049099 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,820 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $40.52 to $41.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 00:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $5.95 | $35,700.00 |
DisclosureSEC source: 0001209191-19-049099 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 20:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-19-044973 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 20:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $45.22 | $271,320.00 |
DisclosureSEC source: 0001209191-19-044973 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $44.975 to $45.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 20:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $3.50 | $21,000.00 |
DisclosureSEC source: 0001209191-19-044973 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2019 Filed Jul 11, 2019 00:18 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-19-041757 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| July 08, 2019 Filed Jul 11, 2019 00:18 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,400 | $43.40 | $60,760.00 |
DisclosureSEC source: 0001209191-19-041757 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $43.13 to $44.07. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 08, 2019 Filed Jul 11, 2019 00:18 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,600 | $42.35 | $194,810.00 |
DisclosureSEC source: 0001209191-19-041757 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,800 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $42.00 to $43.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 08, 2019 Filed Jul 11, 2019 00:18 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $3.50 | $21,000.00 |
DisclosureSEC source: 0001209191-19-041757 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 23:16 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-035661 · doc4.xml · derivative · entry 6 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 23:16 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 3,058 | $38.49 | $117,702.42 |
DisclosureSEC source: 0001209191-19-035661 · doc4.xml · nonDerivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 F2 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $38.18 to $39.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 23:16 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,942 | $37.20 | $109,442.40 |
DisclosureSEC source: 0001209191-19-035661 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,458 F2 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $37.12 to $38.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.